Business
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
PRINCETON, N.J. & BOSTON, July 28, 2025--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical...
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/9f4f9b9595a6888e88d25595330b3c0d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r8RweE9Jf15Th_D.NVZy4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9f4f9b9595a6888e88d25595330b3c0d","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.uRuv8s_QKmLgjtKqGO1bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9f4f9b9595a6888e88d25595330b3c0d","width":1200,"height":165}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bain Capital leads $300 million financing commitment","length":52,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":209,"olType":false},{"type":"text","content":"PRINCETON, N.J. & BOSTON, July 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.","length":487,"tagName":"p"},{"type":"text","content":"The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo’s portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is...